BioAtla, Inc.

Good day and welcome to the BioALTA third quarter 2022 earnings conference call. Pardon me, BioATLA. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on a touch tone phone. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Bruce Meckel from Life Science Advisors. Please, go ahead.

Thank you, Operator, and good afternoon, everyone. With me today on the phone from BioAtla are Dr. Jay Short, Chairman, CEO, and Co-Founder, Scott Smith, President, Philippe Martin, Chief of Clinical Development and Operations, Sherry Lydek, Senior Vice President, Commercial Strategy, and Richard Waldron, Chief Financial Officer. Earlier this afternoon, BioAtla released financial results and a business update for the quarter-ended September 30, 2022. A copy of the press release is available on the company's website. Before we begin, I'd like to remind everyone that statements made during this conference call will include forward-looking statements, including but not limited to statements regarding BioAtlas business plans and prospects, potential selective licensing, collaborations, and other strategic partnerships, whether our clinical trials will be potentially registrational, results conduct, progress, and timing of our research and development programs and clinical trials, expectations with respect to enrollment and dosing in our clinical trials, plans regarding future data updates, clinical trials, regulatory meetings and regulatory submissions, the potential regulatory approval path for our product candidates, expectations about the sufficiency of our cash and cash equivalents, and expected R&D and G&A expenses. These statements are subject to various risks, assumptions, and uncertainties that can cause actual results to differ materially and are described in the filings made with the SEC, including the most recent quarterly report on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today November 3rd, 2022, and BioAtla disclaims any obligation to update such statements to reflect future information, events, or circumstances, except as required by law. With that, I'd like to turn the call over to Jay Short. Jay?

Thank you, Bruce. Thanks to everyone for joining us for our third quarter 2022 BioAtla earnings call. We continue the positive trajectory for advancing the development of our innovative clinical and preclinical programs enabled by the broad applicability of BioAtlas CAB technology. The third quarter was marked by continued strong execution with promising results across our five ongoing Phase II trials for our two latest stage CAB ADC product candidates, BA3011 and BA3021 across multiple solid tumor types for these first-in-class therapeutic candidates. Additionally, we are excited with the continued anti-tumor activity and lack of disease progression along with multiple partial responses as we continue to enroll additional patients in our BA3011 Phase II non-small cell lung cancer study as well as recent feedback from the FDA for from our proposed path forward for our BA3011 Phase II sarcoma study. But before I go any further, I'd like to remind everyone that additional details related to what we are going to present are available on our website as part of our updated company presentation that may be helpful to you. We previously shared interim data on our BA3011 Phase II sarcoma study and our BA3011 Phase II Non-Small Cell Lung Cancer Study, and we now look forward to providing additional insights on both. Further, on today's call, we will discuss additional updates for our other clinical programs. Our Phase II BA3021 studies continue to progress, and we anticipate enrollment completion of up to 20 patients in our Non-Small Cell Lung Cancer Study by year-end for reporting in January. Our validated liquid biopsy assay and the melanoma study is being implemented using our assay before year-end. In addition, our head and neck study is ongoing, and we anticipate dosing multiple patients by year-end. Our phase 1-2 basket trial for our CAB CTLA-4 antibody, BA3071, is progressing nicely with the first two cohorts completed and the third cohort expected by year-end. We also received encouraging pre-IMD feedback from the FDA for our dual-CAB bispecific T-cell engager antibody, EPCAM CD3 or BA3182, and remain on track for an IMD submission of the fourth quarter of this year. Additionally, we remain on track with IMD submissions for up to two next-generation CAB candidates next year. We are pleased with our cumulative results that continue to support both the preliminary efficacy and safety from our differentiated proprietary CAB platform thus far in 2022, and we are well poised to continue with strong execution. We have several additional upcoming catalysts as well as important results to be covered in today's discussion, including exciting updates from our Phase II sarcoma study as well as updates from our Phase II non-small cell lung cancer study with our lead asset, BA3011. With that, I would now like to turn the call over to Philippe for additional details. Philippe?